BR112022004451A2 - Antagonistas de hpk1 e usos dos mesmos - Google Patents
Antagonistas de hpk1 e usos dos mesmosInfo
- Publication number
- BR112022004451A2 BR112022004451A2 BR112022004451A BR112022004451A BR112022004451A2 BR 112022004451 A2 BR112022004451 A2 BR 112022004451A2 BR 112022004451 A BR112022004451 A BR 112022004451A BR 112022004451 A BR112022004451 A BR 112022004451A BR 112022004451 A2 BR112022004451 A2 BR 112022004451A2
- Authority
- BR
- Brazil
- Prior art keywords
- hpk1
- hpk1 antagonists
- antagonists
- inhibition
- compositions
- Prior art date
Links
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
a presente invenção refere-se a compostos, composições dos mesmos e métodos de uso dos mesmos para a inibição de hpk1, e o tratamento de distúrbios mediados por hpk1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962900152P | 2019-09-13 | 2019-09-13 | |
US202063032070P | 2020-05-29 | 2020-05-29 | |
PCT/US2020/050524 WO2021050964A1 (en) | 2019-09-13 | 2020-09-11 | Hpk1 antagonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022004451A2 true BR112022004451A2 (pt) | 2022-06-21 |
Family
ID=74866704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022004451A BR112022004451A2 (pt) | 2019-09-13 | 2020-09-11 | Antagonistas de hpk1 e usos dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (7) | US20210078996A1 (pt) |
EP (1) | EP4027995A4 (pt) |
JP (1) | JP2022547719A (pt) |
KR (1) | KR20220105631A (pt) |
CN (1) | CN114945366A (pt) |
AU (1) | AU2020347274A1 (pt) |
BR (1) | BR112022004451A2 (pt) |
CA (1) | CA3150108A1 (pt) |
CO (1) | CO2022002759A2 (pt) |
IL (1) | IL291244A (pt) |
MX (1) | MX2022002877A (pt) |
TW (1) | TW202126647A (pt) |
WO (1) | WO2021050964A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
CN113227089B (zh) | 2018-10-31 | 2024-07-05 | 吉利德科学公司 | 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
CA3150108A1 (en) * | 2019-09-13 | 2021-03-18 | Neelu Kaila | HPK1 ANTAGONISTS AND THEIR USES |
KR20230003128A (ko) * | 2020-05-01 | 2023-01-05 | 화이자 인코포레이티드 | Hpk1 억제제로서의 아잘락탐 화합물 |
CN112047942B (zh) * | 2020-10-26 | 2022-01-18 | 都创(上海)医药科技股份有限公司 | 一种7-氟咪唑并[1,2-a]吡啶的合成方法 |
JP2024506909A (ja) * | 2021-02-12 | 2024-02-15 | ニンバス サターン, インコーポレイテッド | Hpk1アンタゴニスト及びその使用 |
WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
EP4313989A1 (en) * | 2021-03-29 | 2024-02-07 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
CN118019534A (zh) * | 2021-05-06 | 2024-05-10 | 细胞基因公司 | 使用n-((r)-1-(3-氯吡啶-2-基)-2,2,2-三氟乙基)-2-((s)-2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-甲酰胺的治疗方法 |
CN115611925A (zh) * | 2021-07-14 | 2023-01-17 | 轩竹生物科技股份有限公司 | Hpk1抑制剂及其用途 |
EP4373817A1 (en) | 2021-07-20 | 2024-05-29 | Astrazeneca AB | Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer |
EP4380565A1 (en) * | 2021-08-03 | 2024-06-12 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
CN114230514B (zh) * | 2021-11-26 | 2024-05-31 | 渭南瑞联制药有限责任公司 | 一种合成3-氟-2-氨基异烟腈的方法 |
WO2023160577A1 (zh) * | 2022-02-23 | 2023-08-31 | 正大天晴药业集团股份有限公司 | 含有吡咯啉酮的稠合双环化合物 |
WO2023193759A1 (en) * | 2022-04-07 | 2023-10-12 | Insilico Medicine Ip Limited | Hpk1 antagonists and uses thereof |
WO2023208127A1 (zh) * | 2022-04-27 | 2023-11-02 | 南京明德新药研发有限公司 | 杂芳基取代的双环化合物及其应用 |
WO2023237085A1 (zh) * | 2022-06-10 | 2023-12-14 | 贝达药业股份有限公司 | Hpk1抑制剂及其在医药上的应用 |
TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
CN114940683B (zh) * | 2022-07-26 | 2023-01-17 | 轩竹(北京)医药科技有限公司 | Hpk1抑制剂及其用途 |
WO2024078448A1 (zh) * | 2022-10-10 | 2024-04-18 | 珠海宇繁生物科技有限责任公司 | 一种hpk1激酶抑制剂及其制备方法和应用 |
WO2024140679A1 (en) * | 2022-12-26 | 2024-07-04 | Insilico Medicine Ip Limited | Spirocyclic hpk1 antagonists and uses thereof |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2475569A (en) | 1944-02-07 | 1949-07-05 | American Cyanamid Co | Substituted pyridine compound |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
AP1905A (en) | 1999-12-10 | 2008-10-20 | Pfizer Prod Inc | Pyrrolo[2,3-d] Pyrimidine Compounds. |
EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
BRPI0409063A (pt) | 2003-04-03 | 2006-03-28 | Semafore Pharmaceuticals Inc | pró medicamentos de inibidor de pi-3 cinase |
EP1644363B1 (en) | 2003-05-30 | 2012-02-22 | Gemin X Pharmaceuticals Canada Inc. | Triheterocyclic compounds, compositions, and methods for treating cancer |
US7129260B2 (en) * | 2003-06-02 | 2006-10-31 | Abbott Laboratories | Isoindolinone kinase inhibitors |
WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
US7932260B2 (en) | 2004-05-13 | 2011-04-26 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
US7745641B2 (en) * | 2005-04-19 | 2010-06-29 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
PT1888550E (pt) | 2005-05-12 | 2014-09-03 | Abbvie Bahamas Ltd | Promotores de apoptose |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
AU2006302179C1 (en) | 2005-10-07 | 2013-06-20 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
RU2589878C2 (ru) | 2005-11-01 | 2016-07-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
LT2474545T (lt) | 2005-12-13 | 2017-02-27 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
NZ572812A (en) | 2006-04-26 | 2010-09-30 | Hoffmann La Roche | THIENO [3, 2-D] PYRIMIDINE Indazole DERIVATIVE USEFUL AS PI3K INHIBITOR |
EP2201840B1 (en) | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
WO2008047831A1 (fr) * | 2006-10-17 | 2008-04-24 | Kyowa Hakko Kirin Co., Ltd. | Inhibiteurs de JAK |
ES2557930T3 (es) | 2007-03-12 | 2016-01-29 | Ym Biosciences Australia Pty Ltd | Compuestos de fenilaminopirimidina y usos de los mismos |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
JP5932217B2 (ja) | 2007-07-12 | 2016-06-08 | ジーアイティーアール, インコーポレイテッド | Gitr結合分子を使用する併用療法 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
RS55263B1 (sr) | 2008-03-11 | 2017-02-28 | Incyte Holdings Corp | Derivati azetidina i ciklobutana kao jak inhibitori |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
TW201100441A (en) * | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
US8709424B2 (en) | 2009-09-03 | 2014-04-29 | Merck Sharp & Dohme Corp. | Anti-GITR antibodies |
WO2011056652A1 (en) | 2009-10-28 | 2011-05-12 | Newlink Genetics | Imidazole derivatives as ido inhibitors |
CA2780692C (en) | 2009-12-10 | 2018-09-11 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
SG183847A1 (en) | 2010-03-04 | 2012-10-30 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
US8206715B2 (en) | 2010-05-04 | 2012-06-26 | Five Prime Therapeutics, Inc. | Antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
EP2614082B1 (en) | 2010-09-09 | 2018-10-03 | Pfizer Inc | 4-1bb binding molecules |
ES2700966T3 (es) | 2010-12-09 | 2019-02-20 | Univ Pennsylvania | Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer |
NO2694640T3 (pt) | 2011-04-15 | 2018-03-17 | ||
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
WO2013086397A1 (en) | 2011-12-08 | 2013-06-13 | Array Biopharma Inc. | Urea compounds as gka activators |
WO2013087699A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
WO2013169264A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
TWI713436B (zh) | 2012-08-31 | 2020-12-21 | 美商戊瑞治療有限公司 | 用結合群落刺激因子1受體(csf1r)之抗體治療病狀之方法 |
BR112015010244A8 (pt) | 2012-11-08 | 2019-10-01 | Bristol Myers Squibb Co | compostos de piridila substituída por alquil-amida úteis como moduladores de il-12, il-23 e/ou respostas de ifnalfa, sua composição farmacêutica e seu uso |
ES2702148T3 (es) | 2012-11-08 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida útiles como moduladores de il-12, il-23 y/o ifn-alfa |
CN105992768B (zh) | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
JP6526065B2 (ja) | 2014-02-28 | 2019-06-05 | ニンバス ラクシュミ, インコーポレイテッド | Tyk2阻害剤およびその使用 |
WO2016101119A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
KR101660863B1 (ko) * | 2015-04-03 | 2016-09-28 | 주식회사 녹십자 | IKKε 및 TBK1 억제제로서의 7-아자인돌 또는 4,7-다이아자인돌 유도체 및 이를 포함하는 약학적 조성물 |
KR101846475B1 (ko) * | 2015-04-27 | 2018-04-09 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
IL283353B (en) * | 2015-06-25 | 2022-09-01 | Univ Health Network | hpk1 inhibitors and methods of using them |
CN108699077B (zh) * | 2016-01-15 | 2021-03-02 | 英安塔制药有限公司 | 作为rsv抑制剂的杂环化合物 |
US20190119236A1 (en) * | 2016-02-23 | 2019-04-25 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
TW201811799A (zh) * | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
CN110312711A (zh) * | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | 作为ras抑制剂的杂环化合物及其使用方法 |
JP7025426B2 (ja) * | 2016-11-30 | 2022-02-24 | アリアド ファーマシューティカルズ, インコーポレイテッド | 造血前駆体キナーゼ1(hpk1)阻害剤としてのアニリノピリミジンas |
EP3555064B9 (en) | 2016-12-16 | 2023-03-01 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
US10407424B2 (en) * | 2017-03-30 | 2019-09-10 | Genentech, Inc. | Naphthyridines as inhibitors of HPK1 |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
WO2019090198A1 (en) * | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
US10745388B2 (en) * | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) * | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US20200038378A1 (en) | 2018-04-01 | 2020-02-06 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
PT3873600T (pt) | 2018-10-29 | 2023-12-15 | Boehringer Ingelheim Int | Derivados de piridinil sulfonamida, composições farmacêuticas e suas utilizações |
CA3150108A1 (en) * | 2019-09-13 | 2021-03-18 | Neelu Kaila | HPK1 ANTAGONISTS AND THEIR USES |
WO2021262684A1 (en) * | 2020-06-22 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION |
-
2020
- 2020-09-11 CA CA3150108A patent/CA3150108A1/en active Pending
- 2020-09-11 KR KR1020227012023A patent/KR20220105631A/ko active Search and Examination
- 2020-09-11 US US17/018,591 patent/US20210078996A1/en active Pending
- 2020-09-11 EP EP20862150.8A patent/EP4027995A4/en active Pending
- 2020-09-11 WO PCT/US2020/050524 patent/WO2021050964A1/en unknown
- 2020-09-11 CN CN202080072523.0A patent/CN114945366A/zh active Pending
- 2020-09-11 MX MX2022002877A patent/MX2022002877A/es unknown
- 2020-09-11 BR BR112022004451A patent/BR112022004451A2/pt unknown
- 2020-09-11 JP JP2022516403A patent/JP2022547719A/ja active Pending
- 2020-09-11 AU AU2020347274A patent/AU2020347274A1/en active Pending
- 2020-09-14 US US17/020,173 patent/US11021481B2/en active Active
- 2020-09-14 US US17/020,050 patent/US11028085B2/en active Active
- 2020-09-14 US US17/020,122 patent/US11034694B2/en active Active
- 2020-09-14 TW TW109131550A patent/TW202126647A/zh unknown
- 2020-09-14 US US17/020,013 patent/US11078201B2/en active Active
-
2021
- 2021-07-12 US US17/305,632 patent/US11548890B1/en active Active
-
2022
- 2022-03-09 CO CONC2022/0002759A patent/CO2022002759A2/es unknown
- 2022-03-09 IL IL291244A patent/IL291244A/en unknown
-
2023
- 2023-07-11 US US18/350,536 patent/US20240025898A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11548890B1 (en) | 2023-01-10 |
US20210087190A1 (en) | 2021-03-25 |
EP4027995A4 (en) | 2023-08-23 |
IL291244A (en) | 2022-05-01 |
US11034694B2 (en) | 2021-06-15 |
CO2022002759A2 (es) | 2022-06-21 |
WO2021050964A1 (en) | 2021-03-18 |
US20210078996A1 (en) | 2021-03-18 |
JP2022547719A (ja) | 2022-11-15 |
AU2020347274A1 (en) | 2022-03-31 |
US20240025898A1 (en) | 2024-01-25 |
US11028085B2 (en) | 2021-06-08 |
US11078201B2 (en) | 2021-08-03 |
KR20220105631A (ko) | 2022-07-27 |
US11021481B2 (en) | 2021-06-01 |
CN114945366A (zh) | 2022-08-26 |
MX2022002877A (es) | 2022-08-08 |
CA3150108A1 (en) | 2021-03-18 |
US20210078997A1 (en) | 2021-03-18 |
EP4027995A1 (en) | 2022-07-20 |
TW202126647A (zh) | 2021-07-16 |
US20210078998A1 (en) | 2021-03-18 |
US20210087189A1 (en) | 2021-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022004451A2 (pt) | Antagonistas de hpk1 e usos dos mesmos | |
BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
ECSP16067303A (es) | Heteroarilos y usos de estos | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
BR112018067408A2 (pt) | formas sólidas de um inibidor de acc de tienopirimidinadiona e métodos para a produção das mesmas | |
BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
BR112021016620A2 (pt) | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais | |
EA201891910A1 (ru) | Гетероарильные ингибиторы pad4 | |
EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
EA201792214A1 (ru) | Соединения замещенного хиназолина | |
BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
BR112018075569A2 (pt) | pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos | |
BR112018011709A2 (pt) | inibidores bicíclicos de pad4 | |
EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
BR112016022855A2 (pt) | composições e métodos para modular a expressão de pkk | |
UY38806A (es) | Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos | |
EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
BR112023020781A2 (pt) | Moduladores de cbl-b e usos dos mesmos | |
BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
BR112018011633A2 (pt) | inibidores de aza-benzimidazol de pad4 | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
BR112023015590A2 (pt) | Antagonistas de gpr84 e usos dos mesmos | |
BR112023015210A2 (pt) | Inibidores de cdk2 e métodos de uso dos mesmos | |
BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina |